Real-world data link psychedelic therapy to reduced depression and anxiety in people with severe symptoms, with larger gains tied to stronger acute effects

Psychedelic therapy is associated with meaningful reductions in depression and anxiety among people who began treatment with severe symptoms. Real-world outcomes indicate the largest improvements occurred in participants who reported more intense acute psychedelic effects and stronger shifts in psychological flexibility, connectedness, and emotional breakthrough. The dataset appears to draw from naturalistic clinical practice rather than a tightly controlled lab trial, which makes the findings more reflective of how psychedelic therapy is currently used outside research settings. The reported benefits span severe distress and suggest that subjective experience during treatment may help explain why some people improve more than others. These results matter because severe depression is often difficult to treat, and real-world evidence can complement randomized trials by showing whether benefits hold up in broader populations, varied therapeutic contexts, and routine care.